The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …

Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …

Small cell lung cancer (SCLC) is an extremely aggressive neuroendocrine tumor,
accounting for approximated 13% of all lung cancer cases. SCLC is characterized by rapid …

Lung cancer is the leading cause of cancer-related deaths worldwide. With a focus on
histology, there are two major subtypes: Non-small cell lung cancer (NSCLC)(the more …

Background The genotypic and histological evolution of non-small cell lung cancer (NSCLC)
to small cell lung cancer (SCLC) has been described as a mechanism of acquired …

Following the results of the CROWN phase III trial, the third-generation macrocyclic ALK
inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI …

Precision oncology has fundamentally changed how we diagnose and treat cancer. In
recent years, there has been a significant change in the management of patients with …

The last decade has witnessed a transformation in the treatment of advanced-stage lung
cancer from a largely palliative approach to one where long-term durable remissions and …

To date, several studies have described the mechanism of resistance to first‐or second‐
generation anaplastic lymphoma kinase (ALK) inhibitors. Secondary ALK mutations, ALK …

Discussion Although most patients with ALK-rearranged LUAD benefit from ALK-TKIs,
acquired resistance occurs eventually. Approximately 50–66% of acquired resistance …